John E. Linnehan

John E. Linnehan leads our Health Economics and Advanced Analytics Practice, a team of consultants, strategists, and data scientists focused on driving healthcare improvement through value demonstration, stakeholder engagement, predictive and applied analytics, and data innovations.

His team of experts, extracting knowledge and insights from one of the largest US patient data sources, supports a diverse array of healthcare stakeholders including commercial, HEOR, medical, and public policy professionals at biopharmaceutical companies, device manufacturers, health plans, delivery networks, patient advocacy groups, and medical societies.

John’s technical expertise is grounded in HEOR and using evidence-based medicine to achieve commercial aims and long-term strategic planning. He has a strong background in sales and new business development, and regularly advises healthcare executives on maximizing commercial and medical potential within a dynamic and complex healthcare ecosystem. An accomplished public speaker, he presents regularly at conferences, national meetings, and academic environments.

Prior to joining Avalere, John served as a health economist at Oxford Outcomes (now part of ICON) and a research associate within the Health Economics practice at United BioSource Corporation (now Evidera).

John holds an MPH from The Johns Hopkins Bloomberg School of Public Health, an MBA from The Johns Hopkins Carey Business School, and a BA in biology from the University of Pennsylvania. His research has been published in numerous peer-reviewed journals.

Authored Content

Avalere experts examined evolving stakeholder-specific considerations for reshaping how patients with autoimmune conditions receive care during and after the COVID-19 pandemic.

The collaboration leverages the Inovalon MORE2 Registry® payer-sourced dataset and Corrona’s platform of clinical registries to enable data-driven insights on the treatment of autoimmune diseases from both clinical and health economic perspectives.

Cost savings and improved clinical outcomes cited as top advantages for payers according to survey conducted by Avalere Health.

In the coming months, Avalere experts will be presenting new data and research at major conferences, featuring insights derived from Inovalon’s Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry®).

On January 10, Avalere experts examined the top healthcare priorities to watch in 2019.

Avalere recently partnered with the National Association of Chain Drug Stores (NACDS) to explore the role that pharmacists can play in the uptake of seasonal influenza immunizations.

Avalere experts examine the challenges and successful approaches to outcomes-based contracts.

Avalere experts say use of outcomes-based contracts could further goals to improve patient outcomes and manage drug costs

Hepatitis C and Oncology Are Top Therapeutic Area Targets

New Avalere research shows market demand for real world evidence (RWE), but a lack of stakeholder consensus on how to define it.